series-a
Stage
About
PRD Therapeutics develops first-in-class oral drugs targeting SOAT2 to treat rare lipid metabolism disorders such as homozygous familial hypercholesterolemia (HoFH) and aims to expand into metabolic-associated fatty liver disease and other lipid-related diseases.
Explore PRD Therapeutics, Inc.'s full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.